当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
CNJ-016, Vaccinia Immune Globulin Intravenous (Human)
申请企业
Emergent BioSolutions Canada Inc.
药品名称
CNJ-016, Vaccinia Immune Globulin Intravenous (Human)
承诺描述
Work with the FDA, and other public agencies as appropriate, to design and implement a clinical study protocol to include VIGIV dose ranging, and conduct a study to describe the treatment and clinical course of patients receiving VIGIV for complications of vaccinia infection when such a study is feasible, due to the actual or impending widespread use of VIGIV.